Form 4: AnaptysBio Chief Legal Officer Sells Shares

AnaptysBio's Chief Legal Officer, Eric J. Loumeau, executed pre-planned option exercises and subsequent sales of company common stock.

Summary

• Eric J. Loumeau, Chief Legal Officer of AnaptysBio, Inc., engaged in a series of transactions involving company common stock and employee stock options.
• Transactions were conducted under a Rule 10b5-1 trading plan adopted on April 11, 2025.
• On December 16, 2025, Loumeau exercised options to acquire 5,000 shares at $14.02 and 7,500 shares at $20.16.
• On December 16, 2025, he sold 8,305 shares at a weighted average price of $44.6756 and 4,195 shares at a weighted average price of $45.2369.
• On December 17, 2025, Loumeau exercised options to acquire 10,000 shares at $14.02.
• On December 17, 2025, he sold 10,000 shares at $46.
• On December 18, 2025, he sold an additional 141 shares at $46.99.
• Following these transactions, Loumeau beneficially owns 8,947 shares directly.
• He also holds 53,000 vested employee stock options and additional options to purchase up to 414,810 shares of common stock.

Sentiment

Score: 4

Explanation: The Chief Legal Officer exercised a significant number of options and subsequently sold a similar number of shares, resulting in a net decrease in direct beneficial ownership. While the sales were pre-planned under a 10b5-1 plan, which reduces the negative signal, a net insider sale can still be perceived as a slight negative by investors.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, indicating a planned sale rather than a reaction to new, non-public information.
• The exercise of options demonstrates the executive's prior commitment to the company and the value of their compensation package.
• The sale prices ($44.6756 to $46.99) are significantly higher than the exercise prices ($14.02 to $20.16), indicating a substantial profit for the executive.

Negatives

• The Chief Legal Officer sold a significant number of shares (22,641 shares) over three days.
• The net effect of the reported transactions is a decrease in direct beneficial ownership of common stock from an implied higher amount (before sales) to 8,947 shares.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• The reported transactions involve the Chief Legal Officer of AnaptysBio, Inc. exercising employee stock options and selling common stock, which are considered related party transactions due to the insider nature.

Stakeholder Impact

• Shareholders: May interpret the insider sale as a slight negative signal, although the 10b5-1 plan mitigates this. The executive's profit from option exercises could be seen as a positive for executive alignment.

Key Dates

Recommendation

The filing details routine insider transactions (option exercises and sales) executed under a pre-planned 10b5-1 trading plan. While there's a net sale of shares, the pre-planned nature and the executive's remaining significant option holdings suggest these are for personal financial management rather than a negative outlook on the company. Without additional information on company performance or strategic shifts, these transactions alone do not warrant a change in investment thesis, thus a "hold" recommendation is appropriate.

Keywords

AnaptysBio, ANAB, Form 4, Insider Trading, Stock Option Exercise, Share Sale, Chief Legal Officer, Eric J. Loumeau, 10b5-1 Plan, Biotechnology, Pharmaceuticals